We’ve just put new protocol on the CiRA website. http://www.cira.kyoto-u.ac.jp/e/research/protocol.html [ Generation and culture of Human iPS Cells under feeder-free condition ] > See the protocol (PDF) | Updated: March 11, 2014
A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells
In a joint research project with Osaka University and Ajinomoto Co., Inc., a research team led by Masato Nakagawa (lecturer at Kyoto University, CiRA) and Professor Shinya Yamanaka (Kyoto University, CiRA) has developed a new method for generation and maintenance culture of induced pluripotent stem cells (iPS cells) that are suitable for use in cell transplantation therapy. In order to use human iPS/ES cells in regenerative medicine, the cells must be prepared using methods compliant […]
Embryonic stem cells (ESCs) are established by blastocyst in vitro culture and have an ability to proliferate infinitely with maintaining differentiation ability into three germ layers, named pluripotency. Previously, we identified ECATs (ES Cells Associated Transcripts) as genes which are expressed in undifferentiated ESCs and germ cells but not in somatic cells. Functional analysis revealed that many ECATs, for example Nanog(Ecat4), Eras(ECAT5) and Sall4(Ecat24), are important for undifferentiated ESC properties. However, there are still many […]
Unfortunately there are no vacancies at this moment.
Nakagawa group website has been launched! Please feel free to browse through the site and get to know us better.
Induced pluripotent stem cells (iPSC) are generated from mouse and human fibroblasts by the introduction of three transcription factors, namely Oct3/4, Sox2, and Klf4. The protooncogene product c-Myc markedly promotes iPSC generation, but it also increases tumor formation in iPSC-derived chimera mice. We herein show that the promotion of iPSC generation by Myc is independent of its transformation property. We found that another Myc family member called L-Myc, as well as c-Myc mutants (W136E and […]
Mouse iPS cells are indistinguishable from ES cells in many aspects and produce germline-competent chimeras. Reactivation of the c-Myc retrovirus, however, results in an increased tumorigenicity in the chimeras and progeny mice, thus hindering clinical applications. In the current study, we developed a modified protocol for the induction of iPS cells, which does not require the Myc retrovirus. Elimination of c-Myc sharply reduces tumorigenesis, as measured by cancer-related deaths of chimeric mice derived from iPS […]
CiRA Foundation is now accepting applications for the free provision of iPS cells made from COVID-19 convalescent patientshttps://t.co/ERekDkgAiE— 公益財団法人 京都大学iPS細胞研究財団 (@CiRA_F_J) March 25, 2021
Happy to share this review article by Prof. Yamanaka & Dr. Nakagawa, Kyoto Univ. CiRA which describes the history of #iPSCs with StemFit, from discovery to clinical applications. https://t.co/DR1paaCn1r— StemFit (@fit_stem) October 5, 2020
We are pleased that StemFit supports their activities in iPSCs R&D! pic.twitter.com/CMIUUSxNGR